4 hours agoWHAT MESO needs to done at the typeA meeting is that they need to bring patients and parents of children to testify and show FDA that it gives a chance or cure or better. That's what SRPT has done back in year 2016, even AdComm voted against the SRPT's DMD for insufficient evidences, and follow by FDA comment, they will not approve any drug without enough evidences regarding the approval with SRPT, that is what FDA actually said. But on the date of PDUFA, FDA approved, prior to this decision, the chief FDA resigned who was strongly against the SRPT. Is that an awkward ? SRPT price? was cut in half, when voted against, $21->> $11, and over $150 now, that f*#$#4 FDA !!! I had to sold all my shares due to FDA's comment and ADcom voted against. If FDA hadn't said a word, I would have held it til the day, the voted was only 3:4? 8:9? something.
- Forums
- ASX - By Stock
- MSB
- MSB to dispute FDA finding in Type A meeting
MSB to dispute FDA finding in Type A meeting, page-231
-
-
- There are more pages in this discussion • 787 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
94.0¢ |
Change
-0.020(2.08%) |
Mkt cap ! $1.073B |
Open | High | Low | Value | Volume |
95.5¢ | 97.0¢ | 93.5¢ | $1.424M | 1.507M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 29390 | 93.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
94.5¢ | 14089 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 24054 | 0.935 |
8 | 131583 | 0.930 |
4 | 65851 | 0.925 |
7 | 113334 | 0.920 |
9 | 97006 | 0.915 |
Price($) | Vol. | No. |
---|---|---|
0.945 | 1100 | 1 |
0.950 | 19026 | 2 |
0.955 | 27000 | 2 |
0.960 | 32869 | 2 |
0.965 | 35384 | 2 |
Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online